The UK and US have reached a key trade agreement that will keep no duties on British pharmaceutical exports entering the US market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has agreed to boost expenditure on pharmaceuticals through the public health system. This pledge ensures that duties on these crucial goods will be held at nothing for a duration of three years.
This agreement is in response to recent threats to dramatically increase duties on branded pharmaceutical products, with increases discussed reaching one hundred percent.
"This deal between the UK reinforces the worldwide climate for new treatments and establishes much-needed equity to transatlantic drug exports," a release noted.
Commercial Importance
Drugs constitute one of the UK's most significant export categories to the US, which is by far the largest destination for large companies like GSK and AstraZeneca.
Statistics indicate that in the year to the end of September, the UK exported pharmaceutical products valued at £11.1bn to the US. This figure made up nearly one-fifth of all goods exports in that span.
"This guarantee safeguards employment, increases investment and facilitates the UK to emerge as a worldwide center for life sciences," the Business and Trade Secretary remarked.
Detailed British Pledges
The pact entails several key changes from the British government:
- Price Threshold Increase: The UK will raise the affordability limit at which it deems new medicines to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a goal to double overall NHS spending on medicines from 0.3% of Gross Domestic Product to 0.6% over the coming ten years.
- Refund Ceiling: The amount drug companies must return to the NHS to prevent overspending will be restricted at fifteen percent. Previously, repayments exceeded 20%.
Industry Background
The deal follows a long-running tension between the drug companies and the British authorities over drug pricing and NHS adoption.
These tensions were intensified by claims that US customers were paying significantly more for the identical medicines than consumers in the other developed nations.
Recently, several major drug company projects in the UK have been paused or scrapped, while major expansions have been directed toward American operations.
The Science Minister acknowledged that the NHS must invest a greater share on drugs, noting that its spending on drugs had decreased as a percentage of its overall budget over the last ten years.
